Stock Analiz

Roivant Sciences Ltd. (ROIV) financials: revenue, earnings and cash flow

Fiscal 2021–2026 + TTM · from SEC filings · data as of November 13, 2026

Summary

Roivant Sciences’s revenue went from $24M in fiscal 2021 to $8M in fiscal 2026, a decline of about 19.1% a year.

Net income in fiscal 2026 was -$300M, a net margin of -3629.2%; the best year in this period was 2024 with $4.3B.

Over the twelve months to September 30, 2026, revenue was $41M and net income -$344M.

Free cash flow was -$759M in fiscal 2026 and positive in 0 of the 6 years shown.

The diluted share count rose 10% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2021: $24M20212022: $55M20222023: $32M20232025: $29M20252026: $8M2026$8M
Net income
2021: -$809M20212022: -$845M20222023: -$1.0B20232024: $4.3B20242025: -$172M20252026: -$300M2026-$300M
Free cash flow
2021: -$558M20212022: -$695M20222023: -$856M20232024: -$767M20242025: -$844M20252026: -$759M2026-$759M
EPS (diluted)
2021: $-1.2820212022: $-1.2620222023: $-1.4220232024: $5.2320242025: $-0.2420252026: $-0.542026$-0.54

Income statement

Fiscal yearTTM202620252024202320222021
Revenue$41M$8M$29M—$32M$55M$24M
Gross profit———————
Operating income-$558M-$515M-$1.0B$4.5B-$907M-$1.4B-$1.1B
Net income-$344M-$300M-$172M$4.3B-$1.0B-$845M-$809M
EPS (diluted)$-0.57$-0.54$-0.24$5.23$-1.42$-1.26$-1.28
R&D$712M$682M$550M$440M$454M$483M$237M
Revenue growth—−71.6%——−43.0%+132.3%—

Cash flow

Fiscal yearTTM202620252024202320222021
Operating cash flow-$36M-$750M-$839M-$765M-$843M-$678M-$552M
Capital spending-$3M-$8M-$5M-$1M-$13M-$17M-$6M
Free cash flow-$39M-$759M-$844M-$767M-$856M-$695M-$558M
Dividends paid—$0$0$0$0$0$0
Buybacks——$1.3B$0$0——
Stock-based pay$345M$346M$289M$200M$218M$565M$85M

Balance sheet

Fiscal yearTTM202620252024202320222021
Cash—$4.3B$4.9B$6.5B$1.7B$2.1B$2.1B
Debt—$107M$100M$488M$441M$284M$245M
Equity—$4.5B$4.7B$6.0B$1.2B$1.7B$1.8B
Total assets—$5.7B$5.4B$7.2B$2.4B$2.6B$2.6B
Shares (diluted)723M694M725M831M713M670M630M

Margins and returns

Fiscal yearTTM202620252024202320222021
Gross margin———————
Operating margin-1358.1%-6235.7%-3453.3%—-2875.9%-2444.8%-4500.5%
Net margin-838.2%-3629.2%-592.0%—-3200.2%-1528.9%-3400.9%
FCF margin-96.0%-9183.5%-2905.2%—-2715.1%-1257.4%-2344.8%
ROIC—-8.8%-16.6%69.3%-44.8%-55.0%-41.4%
ROE—-6.6%-3.7%72.9%-87.2%-51.0%-45.0%

Frequently asked questions

What is Roivant Sciences’s annual revenue?

$8M in fiscal 2026 and $41M over the twelve months to September 30, 2026.

How much profit does Roivant Sciences make?

Net income was -$300M in fiscal 2026 (net margin -3629.2%).

Is Roivant Sciences’s revenue growing?

No: revenue fell 71.6% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.